Outlook for 2012 US Copaxone sales (three posts): #msg-75390703 #msg-75406710 #msg-75406857 The bottom line, IMO, is that 2012 US sales of Copaxone (assuming no generic) will be in the neighborhood of $2.6B.
Hmmmm - and all 3 posts by you Dew !
Insofar as the central fact you cite, that:
"Teva did not formally change its guidance ... for $3.8B of worldwide Copaxone sales in 2012 (#msg-70158971)"
- appears refuted by the truth, which is that the new CEO withdrew all 2012 guidance -
- then it would appear that these 3 posts, and the multiple others by genisi and yourself on the BV board today, are ..... shall we say, a bit contrived.
Teva’s new CEO retained 2012 Copaxone guidance for worldwide sales of $3.8B (#msg-75927109); this suggests that my $2.6B forecast for 2012 US Copaxone sales in #msg-75407657 is reasonable and is close enough for modeling purposes.
Market Data 
Markets 
AI
